Proteocyte AI is a company dedicated to producing a range of technological solutions that predict a patient’s risk of developing oral cancer, and the arrival of Mr. Cloutier marks a great step forward as the company contnues towards its ambitious North American growth plans.
Over the past 25 years, Mike has served as General Manager, President and CEO of five major pharmaceutical firms and one not-for-profit organization, the Canadian Diabetes Association (now Diabetes Canada).
In 2017, Mike founded a Canadian-based global consulting practice, Accelera Canada Ltd. Accelera Canada provides unique and unparalleled “one stop support” to US and European-based biotech/pharmaceutical companies exploring commercial entry to Canada. In July of 2021, Accelera was acquired by Eversana Life Sciences Services.
Over the past four years he has developed a more entrepreneurial profile and engaged in the start-up of a number of Life Sciences-related companies. Most recently, he co-founded Noviscend (Accelera MedTech Canada Inc.) to provide consultation, in-licensing and distribution to US and EU-based medical device innovators.
“Mike brings a long, successful track record in working in the medtech space, bringing start-ups from conception to commercialization,” says Proteocyte CEO Mark Hammar. “He has an extensive network of partners in both the healthcare space as well as in investment circles – both critical areas that will help take Proteocyte to broader commercialization in Canada and the U.S. I am thrilled to have Mike join us in this capacity.”
Proteocyte is a personalized medical diagnostics company located in MaRS Centre, Toronto, ON. Proteocyte’s product helps tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte™, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.